Ignite Creation Date:
2024-05-06 @ 1:31 AM
Last Modification Date:
2024-10-26 @ 11:05 AM
Study NCT ID:
NCT01827137
Status:
COMPLETED
Last Update Posted:
2020-01-10
First Post:
2013-04-02
Brief Title:
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sponsor:
Sellas Life Sciences Group
Organization:
Sellas Life Sciences Group
Conditions & Keywords Data
Conditions:
| Name |
|---|
| High-Risk Cancer |
| Multiple Myeloma |
| Minimal Residual Disease |
Keywords:
| Name | View |
|---|---|
| High-risk cytogenetics | View |
| WT1 Analog Peptide Vaccine | View |
| 12-288 | View |
| Galinpepimut-S | View |
| GPS | View |
| Maintenance therapy | View |
| Autologous Stem Cell Transplant ASCT | View |
| Lenalidomide | View |
| Immune Response | View |
| Wilms Tumor 1 | View |
| Prevention of progression | View |
| Prevention of relapse | View |
| Immuno-Oncology | View |
| Immunotherapeutic Agent | View |
| Direct Immunizer | View |
| Heteroclitic | View |
| Multivalent | View |
| Post-ASCT maintenance | View |